ABSTRACT This conference grant application requests funds to help support the 24th International Conference on Kaposi's Sarcoma Herpesvirus and Related Agents in 2022. This annual conference, held since 1994, brings together researchers and clinicians working on the oncogenic human herpesvirus, Kaposi's sarcoma herpesvirus (KSHV), and other closely related pathogens. KSHV is the etiological agent of Kaposi's sarcoma (KS), which is still one of the most prevalent cancers in Africa, especially in HIV-1 infected individuals. Requested funds will be used to reduce the conference registration costs for outstanding pre- and post-doctoral trainees, historically under-represented minorities, and scientists from lower income countries, especially those from Africa who study oncogenic DNA viruses and the cancers associating with these viruses. The goals of these meetings are consistent with the mission statements of the NIH, NCI, NIAID, and NIDCR, namely, to advance and promote the pace of research on infections associated with human cancer and other diseases, including in the setting of HIV-AIDS. The KSHV conference will be held in Denver, Colorado, USA, from the afternoon of June 26th through June 29th, 2022. This meeting will further be organized to enable both in-person attendance as well as virtual participation from researchers across the globe who are not able to attend in-person. Costs for the conference will be raised from registration fees paid by the conferees and contributions from host institutions, foundations, and pharmaceutical and biotechnology companies. The major focus of the KSHV meeting is the biology of oncogenic herpesviruses and associated human diseases, with specific emphasis on viral pathogenesis, viral latency and reactivation, viral gene expression and replication, host responses to infection, epidemiology, vaccine development, therapeutic intervention, clinical and translational research. In addition to KSHV, studies related to relevant animal models, including herpesvirus saimiri (HVS), murine gammaherpesvirus-68 (MHV-68), and rhesus rhadinovirus (RRV) will be presented. The 24th International Conference on Kaposi's Sarcoma-Associated Herpesvirus and Related Agents will continue the tradition of this dynamic, annual scientific conference, to bring together a diverse audience of researchers and clinicians to facilitate the conduct of both translational and basic research on KSHV and KS, to foster new collaborations, and to explore novel therapeutic strategies for treating patients with ailments associated with KSHV in diverse populations and geographies, particularly in the context of HIV-AIDS.